Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 26Leukemia, Myeloid, Acute 24Recurrence 12Sarcoma 7Lymphoma, Large B-Cell, Diffuse 6Neoplasm Metastasis 5Neurofibrosarcoma 4Neoplasms, Plasma Cell 4Lymphoma 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Thymoma 2Rhabdoid Tumor 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Melanoma 2Lymphoma, Mantle-Cell 2Liposarcoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Leukemia 2Congenital Abnormalities 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Wilms Tumor 1

Interventions

Rituximab 77Cyclophosphamide 54fludarabine phosphate 50Peripheral Blood Stem Cell Transplantation 44Mycophenolic Acid 34Whole-Body Irradiation 33Tacrolimus 25Cyclosporine 23Busulfan 22Bortezomib 22Dexamethasone 21Etoposide 19ibrutinib 18Melphalan 17Antilymphocyte Serum 17Methotrexate 15Lenalidomide 15Filgrastim 14Radiotherapy 12Bendamustine Hydrochloride 12Sirolimus 10Calcium Dobesilate 10Flow Cytometry 9Everolimus 9Cyclosporins 9zanubrutinib 8Alemtuzumab 7ibritumomab tiuxetan 6Transplantation 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Waldenstrom Macroglobulinemia × selinexor × Clear all
NCT03147885 2025-09-29

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1/2 Active not recruiting
43 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡